p.117 抽出テキスト
for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol 2010;55:2825–32. https://doi.org/10.1016/j.jacc.2010.01.054 936. Murthy VL, Naya M, Taqueti VR, Foster CR, Gaber M, Hainer J, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation 2014;129: 2518–27. https://doi.org/10.1161/CIRCULATIONAHA.113.008507 937. Demir OM, Boerhout CKM, de Waard GA, van de Hoef TP, Patel N, Beijk MAM, et al. Comparison of doppler flow velocity and thermodilution derived indexes of coronary physiology. JACC Cardiovasc Interv 2022;15:1060–70. https://doi.org/10.1016/j.jcin. 2022.03.015 938. Zeiher AM, Schächinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995;92: 1094–100. https://doi.org/10.1161/01.CIR.92.5.1094 939. Sara JD, Widmer RJ, Matsuzawa Y, Lennon RJ, Lerman LO, Lerman A. Prevalence of coronary microvascular dysfunction among patients with chest pain and nonobstructive coronary artery disease. JACC Cardiovasc Interv 2015;8:1445–53. https://doi.org/10. 1016/j.jcin.2015.06.017 940. Chhabra L, Kowlgi NG. Low incidence of diabetes mellitus in coronary microvascular dysfunction: an intriguing association. JACC Cardiovasc Interv 2016;9:395–6. https://doi. org/10.1016/j.jcin.2015.11.017 941. Ishimori ML, Martin R, Berman DS, Goykhman P, Shaw LJ, Shufelt C, et al. Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. JACC Cardiovasc Imaging 2011;4:27–33. https://doi.org/10.1016/j.jcmg. 2010.09.019 942. Recio-Mayoral A, Rimoldi OE, Camici PG, Kaski JC. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging 2013;6:660–7. https://doi.org/10.1016/j. jcmg.2012.12.011 943. Fairweather D. Sex differences in inflammation during atherosclerosis. Clin Med Insights Cardiol 2014;8:49–59. https://doi.org/10.4137/CMC.S17068 944. Recio-Mayoral A, Mason JC, Kaski JC, Rubens MB, Harari OA, Camici PG. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J 2009;30:1837–43. https://doi.org/10.1093/ eurheartj/ehp205 945. Konst RE, Elias-Smale SE, Lier A, Bode C, Maas AH. Different cardiovascular risk factors and psychosocial burden in symptomatic women with and without obstructive coronary artery disease. Eur J Prev Cardiol 2019;26:657–9. https://doi.org/10.1177/ 2047487318814298 946. van der Meer RE, Maas AH. The role of mental stress in ischaemia with no obstructive coronary artery disease and coronary vasomotor disorders. Eur Cardiol 2021;16:e37. https://doi.org/10.15420/ecr.2021.20 947. Suda A, Takahashi J, Hao K, Kikuchi Y, Shindo T, Ikeda S, et al. Coronary functional abnormalities in patients with angina and nonobstructive coronary artery disease. J Am Coll Cardiol 2019;74:2350–60. https://doi.org/10.1016/j.jacc.2019.08.1056 948. Vrints CJ, Bult H, Hitter E, Herman AG, Snoeck JP. Impaired endothelium-dependent cholinergic coronary vasodilation in patients with angina and normal coronary arteriograms. J Am Coll Cardiol 1992;19:21–31. https://doi.org/10.1016/0735-1097(92)90046p 949. Beltrame JF, Sasayama S, Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. J Am Coll Cardiol 1999; 33:1442–52. https://doi.org/10.1016/s0735-1097(99)00073-x 950. Sueda S, Kohno H, Fukuda H, Ochi N, Kawada H, Hayashi Y, et al. Frequency of provoked coronary spasms in patients undergoing coronary arteriography using a spasm provocation test via intracoronary administration of ergonovine. Angiology 2004;55: 403–11. https://doi.org/10.1177/000331970405500407 951. Hung MY, Hsu KH, Hung MJ, Cheng CW, Cherng WJ. Interactions among gender, age, hypertension and C-reactive protein in coronary vasospasm. Eur J Clin Invest 2010;40: 1094–103. https://doi.org/10.1111/j.1365-2362.2010.02360.x 952. Gulati M, Khan N, George M, Berry C, Chieffo A, Camici PG, et al. Ischemia with no obstructive coronary artery disease (INOCA): a patient self-report quality of life survey from INOCA international. Int J Cardiol 2023;371:28–39. https://doi.org/10.1016/j. ijcard.2022.09.047 953. Shaw LJ, Merz CN, Pepine CJ, Reis SE, Bittner V, Kip KE, et al. The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health–National Heart, Lung, and Blood Institute–sponsored Women’s Ischemia Syndrome Evaluation. Circulation 2006;114:894–904. https://doi.org/10. 1161/circulationaha.105.609990 954. Shaw LJ, Shaw RE, Merz CN, Brindis RG, Klein LW, Nallamothu B, et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology–National Cardiovascular Data Registry. Circulation 2008;117:1787–801. https://doi.org/10.1161/ CIRCULATIONAHA.107.726562 955. Gulati M, Cooper-DeHoff RM, McClure C, Johnson BD, Shaw LJ, Handberg EM, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women’s Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med 2009;169:843–50. https://doi. org/10.1001/archinternmed.2009.50 956. Min JK, Dunning A, Lin FY, Achenbach S, Al-Mallah M, Budoff MJ, et al. Age- and sexrelated differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (coronary CT angiography evaluation for clinical outcomes: an international multicenter registry) of 23,854 patients without known coronary artery disease. J Am Coll Cardiol 2011;58:849–60. https://doi.org/10.1016/j.jacc.2011.02.074 957. Jespersen L, Abildstrom SZ, Hvelplund A, Madsen JK, Galatius S, Pedersen F, et al. Burden of hospital admission and repeat angiography in angina pectoris patients with and without coronary artery disease: a registry-based cohort study. PLoS One 2014;9:e93170. https://doi.org/10.1371/journal.pone.0093170 958. Radico F, Zimarino M, Fulgenzi F, Ricci F, Di Nicola M, Jespersen L, et al. Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis. Eur Heart J 2018;39: 2135–46. https://doi.org/10.1093/eurheartj/ehy185 959. Maddox TM, Stanislawski MA, Grunwald GK, Bradley SM, Ho PM, Tsai TT, et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA 2014;312:1754–63. https://doi.org/10.1001/jama.2014.14681 960. Kelshiker MA, Seligman H, Howard JP, Rahman H, Foley M, Nowbar AN, et al. Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis. Eur Heart J 2022;43:1582–93. https://doi.org/10.1093/eurheartj/ ehab775 961. Boerhout CKM, Lee JM, de Waard GA, Mejia-Renteria H, Lee SH, Jung JH, et al. Microvascular resistance reserve: diagnostic and prognostic performance in the ILIAS registry. Eur Heart J 2023;44:2862–9. https://doi.org/10.1093/eurheartj/ehad378 962. Zhou W, Lee Jonan Chun Y, Leung Siu T, Lai A, Lee TF, Chiang JB, et al. Long-term prognosis of patients with coronary microvascular disease using stress perfusion cardiac magnetic resonance. JACC Cardiovasc Imaging 2021;14:602–11. https://doi.org/10. 1016/j.jcmg.2020.09.034 963. Lanza GA, Sestito A, Sgueglia GA, Infusino F, Manolfi M, Crea F, et al. Current clinical features, diagnostic assessment and prognostic determinants of patients with variant angina. Int J Cardiol 2007;118:41–7. https://doi.org/10.1016/j.ijcard.2006.06.016 964. Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. J Am Coll Cardiol 2018;72:2625–41. https://doi.org/10.1016/j.jacc.2018.09.042 965. Sidik NP, Stanley B, Sykes R, Morrow AJ, Bradley CP, McDermott M, et al. Invasive endotyping in patients with angina and no obstructive coronary artery disease: a randomized controlled trial. Circulation 2024;149:7–23. https://doi.org/10.1161/ CIRCULATIONAHA.123.064751 966. Rahman H, Demir OM, Khan F, Ryan M, Ellis H, Mills MT, et al. Physiological stratification of patients with angina due to coronary microvascular dysfunction. J Am Coll Cardiol 2020;75:2538–49. https://doi.org/10.1016/j.jacc.2020.03.051 967. Belmonte M, Pijls NHJ, Bertolone DT, Bertolone DT, Keulards DCJ, Viscusi MM, et al. Measuring absolute coronary flow and microvascular resistance by thermodilution. J Am Coll Cardiol 2024;83:699–709. https://doi.org/10.1016/j.jacc.2023.12.014 968. Feenstra RGT, Woudstra J, Bijloo I, Vink CEM, Boerhout CKM, de Waard GA, et al. Post-spastic flow recovery time to document vasospasm induced ischemia during acetylcholine provocation testing. Int J Cardiol Heart Vasc 2023;47:101220. https:// doi.org/10.1016/j.ijcha.2023.101220 969. Sueda S, Kohno H, Fukuda H, Ochi N, Kawada H, Hayashi Y, et al. Induction of coronary artery spasm by two pharmacological agents: comparison between intracoronary injection of acetylcholine and ergonovine. Coron Artery Dis 2003;14:451–7. https://doi. org/10.1097/00019501-200309000-00006 970. Montone RA, Rinaldi R, Del Buono MG, Gurgoglione F, La Vecchia G, Russo M, et al. Safety and prognostic relevance of acetylcholine testing in patients with stable myocardial ischaemia or myocardial infarction and non-obstructive coronary arteries. EuroIntervention 2022;18:e666–76. https://doi.org/10.4244/eij-d-21-00971 971. Takahashi T, Samuels BA, Li W, Parikh MA, Wei J, Moses JW, et al. Safety of provocative testing with intracoronary acetylcholine and implications for standard protocols. J Am Coll Cardiol 2022;79:2367–78. https://doi.org/10.1016/j.jacc.2022.03.385 972. Montone RA, Niccoli G, Fracassi F, Russo M, Gurgoglione F, Cammà G, et al. Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests. Eur Heart J 2018;39: 91–8. https://doi.org/10.1093/eurheartj/ehx667 973. Layland J, Carrick D, Lee M, Oldroyd K, Berry C. Adenosine: physiology, pharmacology, and clinical applications. JACC Cardiovasc Interv 2014;7:581–91. https://doi.org/ 10.1016/j.jcin.2014.02.009 974. Mizukami T, Sonck J, Gallinoro E, Kodeboina M, Canvedra A, Nagumo S, et al. Duration of hyperemia with intracoronary administration of papaverine. J Am Heart Assoc 2021; 10:e018562. https://doi.org/10.1161/JAHA.120.018562 975. Kern MJ, Deligonul U, Serota H, Gudipati C, Buckingham T. Ventricular arrhythmia due to intracoronary papaverine: analysis of QT intervals and coronary vasodilatory reserve. Cathet Cardiovasc Diagn 1990;19:229–36. https://doi.org/10.1002/ccd. 1810190402 ESC Guidelines 3531 Downloaded from academic.oup.com/eurheartj/article/45/36/3415/7743115 by guest on 07 October 2026